EDINBURGH-based life sciences firm Kynos Therapeutics has won multi-million pound backing as it looks to develop pioneering drugs to help tackle problems caused by inflammation.
The University of Edinburgh spin-out raised £6.5m equity investment in a round led by Epidarex Capital and IP Group and supported by Scottish Enterprise, which said Kynos is developing an innovative portfolio of first-in-class medicines.
The funding announcement noted: “Kynos’s pipeline is focused on three key areas: in critical illness post-surgery; in conditions driven by inflammation; and in cancers where inflammation is preventing the immune system from fighting back.”
The funding round reflects confidence in the potential of assets in the pipeline to tackle the conditions concerned by inhibiting the production of an enzyme called kynurenine 3-monooxygenase (KMO).
Elizabeth Roper, partner at Epidarex Capital, said: “Kynos has a first-in-class set of KMO inhibitors that we believe have potential in multiple therapeutic areas.”
Kynos has also been awarded £2.5m grant support under the Innovate UK progarmme to fund what was described as a first-time in human Phase 1 clinical trial of its lead KMO inhibitor.
The company’s chief executive Damian Mole is Professor of Surgery at the University of Edinburgh Centre for Inflammation Research. Chief scientific officer Scott Webster is Professor of Medicines Discovery.
The announcement notes that the company’s pipeline of KMO inhibitors was originally co-developed through a collaboration between pharmaceutical giant GSK and the University of Edinburgh and is now exclusively licensed to Kynos.
Kerry Sharp, director of growth investments at Scottish Enterprise said: “Scotland is globally renowned for its strengths in life sciences because of our innovative companies, incredible talent and world-class universities.”
Epidarex has offices in Edinburgh and in Maryland in the USA. The firm has invested in a range of companies in Scotland. Its portfolio includes University of Glasgow spin out Clyde Bisosciences, which has developed a technology to evaluate toxicity risk in pharmaceuticals.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here